Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM

Glucotrack, Inc.

Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.
Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.
Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.
R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.
Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Glucotrack, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of.

Period: first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of
Result: reported results

Exact text from the filing

Net Loss: Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of 2025.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.